Trial Profile
A randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the safety and efficacy of FK962 in subjects with mild to moderate Alzheimer's disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2012
Price :
$35
*
At a glance
- Drugs FK 962 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 20 Jul 2006 Status change
- 22 Oct 2005 New trial record.